Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application–and Back Again

[1]  Quin F. Wills,et al.  Toxicogenomics in Drug Discovery and Development — Making an Impact , 2009, Alternatives to laboratory animals : ATLA.

[2]  A. Abate,et al.  Ultrahigh-throughput screening in drop-based microfluidics for directed evolution , 2010, Proceedings of the National Academy of Sciences.

[3]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[4]  N. Thomas.  Review Article: High-Content Screening: A Decade of Evolution , 2010, Journal of biomolecular screening.

[5]  A P Worth,et al.  The Importance of the Prediction Model in the Validation of Alternative Tests , 2001, Alternatives to laboratory animals : ATLA.

[6]  Carl-Fredrik Mandenius,et al.  Report and Recommendations of the Workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity , 2009, Cardiovascular Toxicology.

[7]  Doris A Taylor,et al.  Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart , 2008, Nature Medicine.

[8]  M. Eileen Dolan,et al.  Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci , 2010, Proceedings of the National Academy of Sciences.

[9]  Michael Balls,et al.  Translation of new technologies: from basic research to drug discovery and development. , 2008, Current drug discovery technologies.

[10]  P. O'Brien,et al.  Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. , 2004, Free radical biology & medicine.

[11]  J. Peters,et al.  Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate. , 2005, Cancer letters.

[12]  Carl-Fredrik Mandenius,et al.  Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines — A Report on the Vitrocellomics EU-project , 2011, Alternatives to laboratory animals : ATLA.

[13]  Robert Combes,et al.  New Technologies for Toxicity Testing , 2012, Advances in Experimental Medicine and Biology.

[14]  R. Parkhill,et al.  An Immunologic Model for Rapid Vaccine Assessment — A Clinical Trial in a Test Tube , 2009, Alternatives to laboratory animals : ATLA.

[15]  Angelo Vedani,et al.  In Silico Toxicology in Drug Discovery — Concepts Based on Three-dimensional Models , 2009, Alternatives to laboratory animals : ATLA.

[16]  W. Perman,et al.  Review of Magnetic Resonance Spectroscopy in the Liver and the Pancreas , 2009, Topics in magnetic resonance imaging : TMRI.

[17]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[18]  Krishna Prasad,et al.  Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.

[19]  Tommy B Andersson,et al.  Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.

[20]  T. Nikolskaya,et al.  A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT , 2006, Drug Metabolism and Disposition.

[21]  Komal Rambani,et al.  Culturing thick brain slices: An interstitial 3D microperfusion system for enhanced viability , 2009, Journal of Neuroscience Methods.

[22]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[23]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[24]  T. Hardingham.  Cell- and Tissue-Based Approaches for Cartilage Repair , 2010, Alternatives to laboratory animals : ATLA.

[25]  D. Noble.  Modeling the Heart--from Genes to Cells to the Whole Organ , 2002, Science.

[26]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[27]  G. T. Baxter.  Hurel™ — an In Vivo-surrogate Assay Platform for Cell-based Studies , 2009, Alternatives to laboratory animals : ATLA.

[28]  D. Brenner,et al.  Computed tomography--an increasing source of radiation exposure. , 2007, The New England journal of medicine.

[29]  Robert Combes,et al.  An Overall Strategy for the Testing of Chemicals for Human Hazard and Risk Assessment under the EU REACH System , 2003, Alternatives to laboratory animals : ATLA.

[30]  E. Wanke,et al.  Short-latency cross- and autocorrelation identify clusters of interacting cortical neurons recorded from multi-electrode array , 2009, Journal of Neuroscience Methods.

[31]  A. Corrias,et al.  Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[32]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[33]  P. Stephens.  Development of a Cell-based Diabetic Wound Assay , 2010, Alternatives to laboratory animals : ATLA.

[34]  Johannes Doehmer.  The Use and Value of In Vitro Technologies in Metabolism Studies , 2009, Alternatives to laboratory animals : ATLA.

[35]  Katya Tsaioun,et al.  De-Risking Drug Discovery with ADDME — Avoiding Drug Development Mistakes Early , 2009, Alternatives to laboratory animals : ATLA.

[36]  R. Vasan,et al.  Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.

[37]  Hardev Pandha,et al.  Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer , 2011, Clinical Cancer Research.

[38]  S. Przyborski,et al.  Alvetex®: polystyrene scaffold technology for routine three dimensional cell culture. , 2011, Methods in molecular biology.

[39]  Arun V Holden.  Development and Application of Human Virtual Excitable Tissues and Organs: From Premature Birth to Sudden Cardiac Death , 2010, Alternatives to laboratory animals : ATLA.

[40]  Glyn Stacey,et al.  Current developments in cell culture technology. , 2012, Advances in experimental medicine and biology.

[41]  M. Balls.  Chapter 23:Integrated Testing Strategies and the Prediction of Toxic Hazard , 2010 .

[42]  T Hartung,et al.  Toward an evidence-based toxicology , 2006, Human & experimental toxicology.

[43]  T. Hartung.  Toxicology for the twenty-first century , 2009, Nature.

[44]  Mark T D Cronin,et al.  The Use of a Chemistry-based Profiler for Covalent DNA Binding in the Development of Chemical Categories for Read-across for Genotoxicity , 2011, Alternatives to laboratory animals : ATLA.

[45]  Tsun-Po Yang,et al.  Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies , 2010, Bioinform..

[46]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[47]  Albert P. Li,et al.  The Use of the Integrated Discrete Multiple Organ Co-culture (IdMOC®) System for the Evaluation of Multiple Organ Toxicity , 2009, Alternatives to laboratory animals : ATLA.

[48]  Jan M. Kriegl,et al.  Computational approaches to predict drug metabolism , 2009, Expert opinion on drug metabolism & toxicology.

[49]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[50]  David W Roberts,et al.  The In Chemico–In Silico Interface: Challenges for Integrating Experimental and Computational Chemistry to Identify Toxicity , 2009, Alternatives to laboratory animals : ATLA.

[51]  D. Kendall,et al.  Direct and indirect stimulations of cyclic AMP formation in human brain , 1992, British journal of pharmacology.

[52]  Aniruddh Solanki,et al.  A Step Closer to Complete Chemical Reprogramming for Generating iPS Cells , 2010, Chembiochem : a European journal of chemical biology.

[53]  George Loizou,et al.  Possibilities for a New Approach to Chemicals Risk Assessment — The Report of a FRAME Workshop a , 2006, Alternatives to laboratory animals : ATLA.

[54]  Jehyuk Lee,et al.  Generation of functional human hepatic endoderm from human induced pluripotent stem cells , 2009, Hepatology.

[55]  D. L. Taylor,et al.  A Personal Perspective on High-Content Screening (HCS) , 2010, Journal of biomolecular screening.

[56]  Scott Boyer.  The Use of Computer Models in Pharmaceutical Safety Evaluation , 2009, Alternatives to laboratory animals : ATLA.

[57]  A. Minarini,et al.  Alzheimer's disease: new approaches to drug discovery. , 2009, Current opinion in chemical biology.

[58]  Michael Balls.  Modern Alternative Approaches to the Problem of Drug-induced Liver Injury , 2011, Alternatives to laboratory animals : ATLA.

[59]  Perry L. Miller,et al.  The Human Brain Project: neuroinformatics tools for integrating, searching and modeling multidisciplinary neuroscience data , 1998, Trends in Neurosciences.

[60]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[61]  R. A. Coleman.  A Human Approach to Drug Development: Opportunities and Limitations , 2010, Alternatives to laboratory animals : ATLA.

[62]  Simon Thomas,et al.  Physiologically-based Simulation Modelling for the Reduction of Animal Use in the Discovery of Novel Pharmaceuticals , 2009, Alternatives to laboratory animals : ATLA.

[63]  Robert Combes,et al.  Toxicity testing: creating a revolution based on new technologies. , 2005, Trends in biotechnology.

[64]  D. Holliday.  A Three-dimensional In Vitro Model of Breast Cancer: Toward Replacing the Need for Animal Experiments , 2010, Alternatives to laboratory animals : ATLA.

[65]  M. Cronin.  In Silico Toxicology Challenges for Pharmaceuticals: Complacency or Controversy? , 2009, Alternatives to laboratory animals : ATLA.

[66]  Hans-Michael Müller,et al.  The Neuroscience Information Framework: A Data and Knowledge Environment for Neuroscience , 2008, Neuroinformatics.

[67]  Kathryn A Phillips,et al.  Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. , 2007, Current drug safety.

[68]  E. Kunkel.  Systems biology in drug discovery , 2004, Nature Biotechnology.

[69]  Michael Balls,et al.  Integrated Testing Strategies for Toxicity Employing New and Existing Technologies , 2011, Alternatives to laboratory animals : ATLA.

[70]  Zvia Agur,et al.  Use of Virtual Patient Populations for Rescuing Discontinued Drug Candidates and for Reducing the Number of Patients in Clinical Trials , 2009, Alternatives to laboratory animals : ATLA.

[71]  Alexander G Bassuk,et al.  HeyL promotes neuronal differentiation of neural progenitor cells , 2011, Journal of neuroscience research.

[72]  M Filippi,et al.  Imaging biomarkers in multiple sclerosis , 2010, Journal of magnetic resonance imaging : JMRI.